2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 579

Changes in DNA Methylation Identify Response to Treatment with Methotrexate and TNF Inhibitors Among RA Patients
Abstract Number: 1688

Changes in Heart Rate Variability Reflect Clinical Improvement and Flare in Systemic Lupus Erythematosus
Abstract Number: 685

Changes in Key Laboratory Values with Tofacitinib 5mg BID Treatment in Patients with Psoriatic Arthritis and Rheumatoid Arthritis
Abstract Number: 2586

Changes in Lymphocytes and Lymphocyte Subsets in Tofacitinib-Treated Patients with Psoriatic Arthritis
Abstract Number: 901

Changes in Quantitative Scleroderma Lung CT Measures in Patients Treated with Cyclophosphamide or Transplantation
Abstract Number: 899

Changes in the Systemic Sclerosis Molecular Signatures after Myeloablation Followed By Autologous Hematopoietic Stem Cell Transplantation and Their Clinical Correlates
Abstract Number: 2544

Changes of CD4-(CD8+) Regulatory T Cells in Rheumatoid Arthritis Patients and during Interleukin-2 Therapy
Abstract Number: 1083

Changes of Innate Lymphoid Cells in Peripheral Blood of Patients with Systemic Lupus Erythematosus and Its Correlations with Clinical Markers
Abstract Number: 1946

Changing the Conversation about Pain: Development and Testing of an Interprofessional Pain CME Applicable for Rheumatologists and Rheumatology Health Professionals
Abstract Number: 2956

Changing Trends and Prescribing Patterns in Opioid-Treated Primary Care Patients with Non-Cancer Pain over a 10-Year Period
Abstract Number: 553

Channeling to Treatment and Associated Changes in Disease Activity Over 12 Months in Patients With RA Treated With Abatacept Versus Other DMARDs in Real-World Community Practice Settings
Abstract Number: 2988

Characteristics and Outcomes in a Prospective Cohort of Patients with Aortitis Diagnosed Following Surgical Resection
Abstract Number: 1388

Characteristics and Symptom Severity in 21,101 Patients Reporting Systemic Lupus Erythematous in the Patientslikeme Online Health Community
Abstract Number: 1882

Characteristics and Treatment Outcomes of Takayasu Arteritis in a Nationwide, Retrospective Cohort Study in Japan
Abstract Number: 2488

Characteristics of Difficult-to-Treat Rheumatoid Arthritis: Results of an International Survey

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].